- Home
- GLRE vs OVID Comparison
GLRE vs OVID Comparison
Compare GLRE & OVID Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | GLRE | OVID |
|---|---|---|
| Founded | 2004 | 2014 |
| Country | Cayman Islands | United States |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 501.7M | 562.5M |
| IPO Year | 2007 | 2017 |
Fundamental Metrics
Financial Performance| Metric | GLRE | OVID |
|---|---|---|
| Price | $15.31 | $2.38 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 13 |
| Target Price | N/A | ★ $6.00 |
| AVG Volume (30 Days) | 101.3K | ★ 1.6M |
| Earning Date | 11-02-2026 | 11-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 75.00 | 3.90 |
| EPS | ★ 0.18 | N/A |
| Revenue | ★ $729,777,000.00 | $7,252,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $83.03 | ★ N/A |
| Revenue Growth | 4.85 | ★ 1181.27 |
| 52 Week Low | $11.57 | $1.18 |
| 52 Week High | $19.39 | $3.11 |
Technical Indicators
Market Signals| Indicator | GLRE | OVID |
|---|---|---|
| Relative Strength Index (RSI) | 59.40 | 46.95 |
| Support Level | $14.53 | $2.09 |
| Resistance Level | $15.48 | $2.44 |
| Average True Range (ATR) | 0.38 | 0.17 |
| MACD | 0.07 | 0.02 |
| Stochastic Oscillator | 89.27 | 47.32 |
Price Performance
Historical ComparisonAbout GLRE Greenlight Capital Re Ltd.
Greenlight Capital Re Ltd offers property and casualty reinsurance. Its customers are property and casualty insurers, and Greenlight takes on some of their risk in exchange for insurance premiums. It operates through one operating segment: property and casualty reinsurance. It generates revenue through premiums from reinsurance on property and casualty business assumed and income from investments.
About OVID Ovid Therapeutics Inc.
Ovid Therapeutics Inc is a biopharmaceutical company that is dedicated to reducing seizures and meaningfully improving the lives of people affected by rare epilepsies and seizure-related neurological disorders. The company has built a differentiated pipeline of medicines with potential first-in-class drug mechanisms of action to treat seizures. This pipeline has produced two epilepsy programs with potential first-in-class mechanisms of action, and one epilepsy program with a potential best-in-class mechanism of action.